Dunque il rialzo sarà la conseguenza di queste notizie che sono comparse oggi sul sito dell'intercytex:
Proposed placing of 23,076,924 shares at 52 pence per share raising £12 million
3rd May 2007
Cambridge, UK, 3 May 2007 – Intercytex Group plc (the “Company”) (ICX.L), the cell therapy company focused on aesthetic medicine and tissue repair, today announces its intention to raise £12 million in a Placing of new ordinary shares to institutional investors in the UK and continental Europe.
The Placing is conditional upon, inter alia, the approval of shareholders. A circular convening an EGM of the Company, which is expected to take place on 29 May 2007, is being posted to shareholders today.
Placing Highlights
Intercytex to raise £12 million through the placing of 23,076,924 Placing Shares at a Placing Price of 52 pence per share. The Placing is being fully underwritten by Piper Jaffray and the shares have been placed with new and existing institutional shareholders further widening the institutional shareholder base.
The Placing Price represents a discount of 13.3% to the closing mid-market price of 60 pence per ordinary share as at 2 May 2007, the latest practicable date prior to the announcement of the Placing.
The net proceeds of the fundraising will be approximately £11.4 million.
Intercytex intends to use the funds raised from the Placing as follows:
launch of its facial rejuvenation product, Vavelta, in the UK;
complete the Phase III trial for ICX-PRO and file a BLA;
continue the Phase II programmes for Vavelta and ICX-TRC (for male pattern baldness); and
conduct further trials for ICX-SKN (skin graft replacement).
The necessary authority required to issue and allot the Placing Shares pursuant to the Placing will be sought at an Extraordinary General Meeting convened for 11.00am on 29 May 2007.
Commenting on the proposed Placing, Nick Higgins, Chief Executive of Intercytex, said: “ This fundraising is a significant step forward for Intercytex. It follows an extremely busy and successful period in the history of the Company, in which we have demonstrated our ability to deliver on the objectives set out at IPO by taking the products in our pipeline to the next stages of development. The funds raised will allow us to complete a number of key value-driving steps, including the market launch of our first product, Vavelta, for facial rejuvenation and the completion of the Phase III trial for ICX-PRO.”
Non ho ben capito di cosa si tratti ma credo sia un finanziamento per proseguire gli studi!